Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Genetic variation in response to 6 mercaptopurine for childhood acute lymphoblastic leukemia.
The TPMT variants did not completely explain mercaptopurine toxicity.
This study is the most comprehensive effort yet to identify the genetic basis of mercaptopurine intolerance in young ALL patients.
Possible implication of thiopurine Smethyltransferase in the occurrence of infectious episodes during maintenance therapy of acute leukemia with mercaptopurine.
Performance evaluation of reversed phase HPLC assays for metabolite of mercaptopurine and azathioprine [Poster].
Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine
Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.
HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.
Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.
Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Application of pharmacogenetics to optimization of mercaptopurine dosing.
Patient TPMT TPMT Withdrawal of azathioprine/ genotype activity (a) mercaptopurine because of side effects 162-9 * 1/* 3A 16 Yes 162-58 * 1/* 3A 18 No 150-3 * 1/* 3A 14 Yes 149-9 * 1/* 3A 33 No 149-16 * 1/* 3A 19 Yes 149-40 * 1/* 3A 21 No 140-45 * 1/* 3A 21 Yes 140-49 * 1/* 3A 23 No 140-90 * 1/* 3A 31 No 150-6 * 1S/* 3A 11 Yes 140-105 * 1S/* 3A 14 Yes 149-31 * 1/* 3C 22 Yes 140-15 * 1/* 3D 22 Yes (a) TPMT enzyme activity was measured by HPLC method.
Lifelong maintenance therapy of UC with aminosalicylates, azathioprine, or mercaptopurine
to reduce the risk of relapse is usually recommended.